Given the evidence that the RAS/ERK signalling pathway is a critical mediator of both tumour initiation and maintenance in the pancreas [55] future work should also concentrate on the identification of the critical ERK-dependent targets that are affected by loss of either DUSP5 or DUSP6. This evidence concerns the gene MAPK1 and neoplasm.